Partnership will bring NeuroStar® advanced non-drug therapy for mental health to thousands more patients
MALVERN, Pa., July 25. Feb. 20, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ:STIM), a commercial-stage medical technology company focused on designing, developing and commercializing products that improve the quality of life for patients with neurohealth disorders. , including drug-resistant depression and obsessive-compulsive disorder (OCD), today announced a commercial partnership with Alleviant Health Centers (“Alleviant”), a network of full-service mental health clinics that currently operates five sites in Arkansas and plans to expand its service footprint. Under the partnership agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment for Alleviant and its clinics, with the first six NeuroStar Advanced Therapy systems delivered in 2022.
“We are thrilled to partner with Alleviant to bring more people who need it access to NeuroStar as a new non-drug treatment option for depression,” said Keith J. Sullivan, President and CEO. from Neuronetics. “Alleviant’s commitment to providing innovative solutions and its focus on making the world a better place by improving the lives of others make it an ideal partner for us.”
NeuroStar Advanced Therapy is a non-invasive, drug-free treatment that uses transcranial magnetic stimulation to target key areas of the brain that are underactive in people with major depressive disorder (MDD). NeuroStar is the leading TMS treatment for depression in adult patients and has been shown to be safe and effective, with over 4.5 million treatments given to over 127,000 patients to date. Patients treated with NeuroStar achieved a high response rate of 83% and a remission rate of 62% (Sackeim, et al. 2020).
“I care so much about people who suffer, and believe it is my responsibility to share clinically proven solutions and knowledge to anyone who is burdened with conditions we know how to treat,” said Brian Mears, CRNA , Founder, President and CEO of Alleviant Health Centers. “We were using a different TMS device and decided to partner with Neuronetics because the support they provide to our clinics and the exceptional treatment results with NeuroStar TMS will allow us to continue to grow our suite of TMS services and strengthen the patient-centered care that is so important to healing.
To learn more about NeuroStar® Advanced Therapy, visit www.neurostar.com. To learn more about Alleviant Health Centers, visit www.alleviant.com.
About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its advanced NeuroStar therapy for mental health. NeuroStar is a non-drug, non-invasive treatment that can improve the quality of life for people with neurological conditions when traditional medications have not helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as a supplement for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD who may have symptoms of comorbid anxiety (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest registry of depression outcomes. Neuronetics is committed to transforming lives by delivering exceptional treatment that produces extraordinary results. For safety and prescription information, www.neurostar.com. Neuronetics is committed to transforming lives by providing an exceptional treatment option that produces extraordinary results.
About Alleviant Health Centers Alleviant Health Centers are dedicated to shifting the focus of mental health care in the United States from drug care to a holistic, integrated approach that addresses the whole person. The company’s vision is to lead the transformation of mental health care by providing innovative treatment models, creating health care structures that heal the whole person, and becoming a resource for education, inspiration and empowerment for people with mood disorders and chronic pain.
Investor Contact: Mike Vallie or Mark Klausner ICR Westwicke 443-213-0499 [email protected]
Media Contact: EvolveMKD 646-517-4220 [email protected]